ENDO USA, Inc. – FDA 483, Oct 20, 2025
An FDA inspection of ENDO USA, Inc. in Rochester, MI, a sterile drug manufacturer, revealed significant deficiencies in its manufacturing operations. Observations included inadequately designed equipment leading to aseptic breaches, failures in preventing microbiological contamination through deficient aseptic process simulations and environmental monitoring, and a visual inspection program that could not consistently detect product defects. The firm also failed to thoroughly review unexplained discrepancies, impacting product quality and patient safety.
ID · 2f9d2320-d4c6-4b06-9da5-5a58dc371f64
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.